<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14884">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913105</url>
  </required_header>
  <id_info>
    <org_study_id>CLMB763X2201</org_study_id>
    <nct_id>NCT02913105</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH</brief_title>
  <official_title>A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to assess the effects of LMB763 with respect to safety,
      tolerability, and on markers of liver inflammation in patients with NASH
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2016</start_date>
  <completion_date type="Anticipated">October 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event profile and safety endpoints of LMB763 in patients with NASH</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Transaminase levels</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in % of fat in the liver assessed using MRI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anthropometric assessments (BMI in kg/m^2)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on non-invasive liver fibrosis markers (Enhanced Liver Fibrosis (ELF) panel)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of itch sensation based on a visual analog scale (VAS) rating</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on fasting lipid profile</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LMB763 in plasma: Cmax maximum plasma concentration at steady state</measure>
    <time_frame>Within 60 min prior to dosing, post dose: +/- 15 min up to 2 hrs, +/- 30 min from ≥2 hrs up to 6 hrs on Day 1 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LMB763 in plasma: Tmax time to reach the maximum concentration after drug administration</measure>
    <time_frame>Within 60 min prior to dosing, post dose: +/- 15 min up to 2 hrs, +/- 30 min from ≥2 hrs up to 6 hrs on Day 1 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LMB763 in plasma: AUC area under the concentration-time curve</measure>
    <time_frame>Within 60 min prior to dosing, post dose: +/- 15 min up to 2 hrs, +/- 30 min from ≥2 hrs up to 6 hrs on Day 1 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LMB763 in plasma: Racc the accumulation ratio</measure>
    <time_frame>Within 60 min prior to dosing, post dose: +/- 15 min up to 2 hrs, +/- 30 min from ≥2 hrs up to 6 hrs on Day 1 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LMB763 in plasma: T1/2 the effective half-life based on drug accumulation at steady state</measure>
    <time_frame>Within 60 min prior to dosing, post dose: +/- 15 min up to 2 hrs, +/- 30 min from ≥2 hrs up to 6 hrs on Day 1 and Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>LMB763</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose once daily for 12 weeks (84 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral dose once daily for 12 weeks (84 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMB763</intervention_name>
    <description>Hard Gelatin Capsules</description>
    <arm_group_label>LMB763</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hard Gelatin Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female patients, 18 years or older

          -  Written informed consent

          -  Presence of NASH by histologic evidence (liver biopsy) and elevated alanine
             aminotransferase (ALT), OR phenotypic diagnosis of NASH based on elevated ALT, BMI
             and diagnosis of Type 2 diabetes mellitus

        Exclusion Criteria:

          -  Current use of obeticholic acid (OCA)

          -  New initiation GLP-1 agonists such as liraglutide, exenatide , lixisenatide,
             albiglutide or dulaglutide within 3 months of screening

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential, unless they are using highly effective methods of
             contraception during dosing and for 5 days after stopping study medication

          -  Current or history of significant alcohol consumption for a period of more than 3
             consecutive months within 1 year prior to screening

          -  Clinical evidence of hepatic decompensation or severe liver impairment

          -  Previous diagnosis of other forms of chronic liver disease

          -  Uncontrolled diabetes mellitus

          -  History or current diagnosis of ECG abnormalities

          -  Patients with contraindications to MRI imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Science 37</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Martinez</last_name>
      <phone>213-286-1897</phone>
      <email>diego@science37.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ruane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Pitts</last_name>
      <phone>714-668-1500</phone>
      <email>Nikki.pitts@wcct.com</email>
    </contact>
    <investigator>
      <last_name>Bonnie Bock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Trahan</last_name>
      <phone>352-273-8642</phone>
      <email>Yvette.trahan@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Cusi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Ruhaak</last_name>
      <phone>808-440-4426</phone>
      <email>ron@eastwestresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Fitz-Patrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Swope</last_name>
      <phone>615-832-5530</phone>
      <email>cswope@qualitymedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Robert Herring</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josetta Swearingen</last_name>
      <phone>817-471-1070</phone>
      <email>joswearingen@tcri.us</email>
    </contact>
    <investigator>
      <last_name>Reem Ghalib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia (Newport News Office)</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Soublet</last_name>
      <phone>757-947-3191</phone>
      <email>joyce_soublet@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia (Richmond Office)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Vollum</last_name>
      <phone>804-977-8927</phone>
      <email>susan_vollum@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triumpharma</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ahmad Al-Ghezawi</last_name>
      <phone>+962-6-5350582</phone>
      <email>ahmad@triumpharma.com</email>
    </contact>
    <contact_backup>
      <email>Project.coordinator@triumpharma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Professor Shennak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. David Orr</last_name>
      <phone>64 9 307 4949</phone>
      <email>dorr@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>David Orr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials Ltd</name>
      <address>
        <city>Christchurch</city>
        <zip>8024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Simon Carson</last_name>
      <phone>64 3 337 1979</phone>
      <email>simon@sctrials.co.nz</email>
    </contact>
    <investigator>
      <last_name>Simon Carson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research Tauranga</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Kennett</last_name>
      <phone>64 7 579 0453</phone>
      <email>katie@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Paul Noonan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P3 Research Wellington Unit</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Dean Quinn</last_name>
      <phone>64 4 801 0002</phone>
      <email>dean@p3research.co.nz</email>
    </contact>
    <investigator>
      <last_name>Dean Quinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.trials.novartis.com/en/clinical-trials/nash-clinical-trial/</url>
    <description>CLMB763X2201 Study Website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
